Consequently, multitarget molecules that can inhibit both VEGFR-2 and c-Met simultaneously may be more effective than single target molecules since they can shut down many signaling pathways implicated in tumor angiogenesis, proliferation, and metastasis7,9. The gene discussed is MET; the disease is neoplasm.